Results 111 to 120 of about 91,065 (316)
British Journal of Clinical Pharmacology, EarlyView.Aims Oral administration of (S)‐ketamine for treatment‐resistant depression (TRD), as alternative to the registered intranasal or off‐label intravenous administrations, has high potential. However, it is characterized by an extensive first‐pass metabolism, resulting in low (S)‐ketamine exposure and high levels of active metabolites, including (S ...
Marije E. Otto +5 more
wiley +1 more source
Is there a potential of misuse for Magnolia officinalis compounds/metabolites? [PDF]
, 2017 © 2017 John Wiley & Sons, Ltd.Objective: Magnolia bark contains magnolol, metabolized to tetrahydromagnolol and honokiol, with both GABA-ergic/cannabimimetic activities, hence of possible attraction to vulnerable individuals/recreational misusers ...
Alexeev +32 more
core +3 more sources
Novel psychoactive substances: second and third international conferences
Human Psychopharmacology: Clinical and Experimental, 2015 EDITORIAL
A. C. Parrott, O. Corazza
openaire +5 more sources
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim Individual second‐generation antihistamines may possess differential sedative potential due to the variability in central histamine receptor H1 occupancy. This study aimed to evaluate whether the sedative potential of second‐generation antihistamines is associated with the risk of injury during Japan's pollen season. Methods We conducted a
Jumpei Taniguchi +3 more
wiley +1 more source
The complexity of neuroenhancement and the adoption of a social cognitive perspective [PDF]
, 2015 This contribution attempts to provide a broad perspective to the psychological study of neuroenhancement (NE). It departs from the assumption that, as the use of performance enhancing substances in sport, the use of substances with the aim of improving ...
LUCIDI, Fabio +2 more
core +2 more sources
Novel Psychoactive Spectra: NMR of (mostly) Novel Psychoactive Substances [PDF]
, 2017 1H NMR spectra of classical and novel psychoactive substances (NPS) are reported, including phenylethanamines (2-phenylethan-1-amines), phenylpropanamines (1-phenylpropan-2-amines), N-benzyl-phenylalkanamines, β-keto-phenylalkanamines (2-amino-1-phenylethan-1-ones and 2-amino-1-phenylpropan-1-ones), thiophenylpropanamines (1-(thiophen-2-yl)propan ...
openaire +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim To identify safety concerns reported by coroners following fentanyl patch‐related deaths in England, Wales and Northern Ireland, and determine differences in coronial reporting. Methods A systematic case series linking the National Programme on Substance Use Mortality (NPSUM) and the Preventable Deaths Tracker (PDT) (https ...
Eman Mshari +2 more
wiley +1 more source
Behavioral Sciences, 2020 (1) Introduction: Drug-related deaths in the UK are at concerning high levels. The unknown content and purity of illicit substances can cause unpredictable adverse effects and thus a public health risk with no sign of abating.
Amira Guirguis +2 more
doaj +1 more source
Bulletin of the Korean Chemical Society, EarlyView.Dried blood spot (DBS) analysis enables minimally invasive blood collection with strong analyte stability and simplified logistics, supporting anti‐doping applications beyond traditional matrices. Recent advances address hematocrit, volume variability, and matrix effects while expanding coverage to steroid esters, World Anti‐Doping Agency‐listed ...
Jihyun Yoon +4 more
wiley +1 more source
Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea
Chronic Diseases and Translational Medicine, EarlyView.Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Anish Preshy +3 more
wiley +1 more source